1.Impact of weight loss on cancer-related proteins in serum: results from a cluster randomised controlled trial of individuals with type 2 diabetes

Some research suggests a potential correlation between type 2 diabetes and colorectal, breast, endometrial, gallbladder, liver, and pancreatic cancers, although the precise mechanism remains elusive. This study encompassed 313 participants from clinical trials focusing on diabetes remission, divided into intervention and control groups for a controlled trial. According to the findings, the original authors identified nine pertinent proteins, including glycoprotein Nmb, furin protease, Wnt inhibitory factor 1, toll-like receptor 3, pancreatic hormone, erb-b2 receptor tyrosine kinase 2, hepatocyte growth factor, endothelial cell-specific molecule 1, and Ret proto-oncogene, as associated with the intervention status. This underscores the potential impact of weight management in individuals diagnosed with type 2 diabetes on cancer-related biological pathways.

For more comprehensive insights, please refer to the original text.

DOI:https://doi.org/10.1016/j.ebiom.2024.104977

https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(24)00012-4/fulltext

2.Mycophenolate mofetil withdrawal in patients with systemic lupus erythematosus: a multicentre, open-label, randomised controlled trial

Mycophenolate mofetil (MMF) is a commonly used immunosuppressant for treating systemic lupus erythematosus (SLE). However, it is also a teratogenic drug and can increase the risk of infections and malignant tumors. As for the cessation period of MMF, there is insufficient data for thorough evaluation. A study encompassing 123 patients conducted a randomized controlled trial, dividing participants into maintenance and withdrawal groups.according to the finding，Mycophenolate mofetil withdrawal is not significantly inferior to mycophenolate mofetil maintenance.

For more comprehensive insights, please refer to the original text.

DOI:https://doi.org/10.1016/S2665-9913(23)00320-X

https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(23)00320-X/fulltext

3.Safety and efficacy of laquinimod for Huntington's disease (LEGATO-HD): a multicentre, randomised,double-blind,placebo-controlled,phase2 study

Laquinimod modulates CNS inflammatory pathways thought to be involved in the pathology of Huntington's disease. The study included a total of 352 patients with Huntington's disease in a randomized controlled trial, dividing the participants into a treatment group and a placebo group. According to the results obtained, Laquinimod did not significantly affect the motor symptoms assessed by the Unified Huntington's Disease Rating Scale Total Motor Score (UHDRS-TMS). However, compared to the placebo, Laquinimod significantly reduced caudate nucleus volume loss at week 52.

For more comprehensive insights, please refer to the original text.

DOI:https://doi.org/10.1016/S1474-4422(23)00454-4

https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(23)00454-4/fulltext

4.Ixazomib-based frontline therapy followed by ixazomib maintenance in frail elderly newly diagnosed with multiple myeloma: a prospective multicenter study

The survival rates for frail elderly patients with newly diagnosed multiple myeloma (NDMM) are relatively poor, and high-dose therapy yields limited benefits. This study, a non-randomized, synchronized controlled trial, enrolled a total of 120 patients to explore the efficacy, safety, and quality of life of induction therapy followed by maintenance therapy in frail elderly NDMM patients. According to the results obtained, the IDd regimen did not show significant advantages over the IRd regimen, and the survival period in the IDd group was shorter compared to the IRd group.

For detailed information, please refer to the original text.

DOI:https://doi.org/10.1016/j.eclinm.2024.102431

https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(24)00010-5/fulltext